Producer
Hainan Poly Pharm Co., Ltd.
Chinese pharmaceutical API company (Haikou, Hainan Province; listed on Shanghai Stock Exchange; majority-owned by Poly Group — a state-linked Chinese industrial conglomerate); one of China's largest paclitaxel and docetaxel API manufacturers. Hainan Poly Pharm sources 10-DAB primarily from Taxus chinensis (Chinese yew) cultivated in Yunnan and Sichuan provinces and produces paclitaxel API via semi-synthesis for Chinese domestic oncology drug manufacturers and for export. The company benefits from China's large Taxus plantation base in southern and southwestern provinces and from Poly Group's state-connected supply chain relationships. Hainan Poly Pharm is a significant but not dominant player within China's fragmented paclitaxel API sector.
1
Inputs supplied
1
Goods downstream
2
Facilities
0
Stories
What they make
1 input Hainan Poly Pharm Co., Ltd. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Hainan Poly Pharm Co., Ltd. makes — pick one to see the full supply chain.
Where they make it
2 facilities
Hainan Poly Pharm API Plant (Haikou, Hainan) →
CNHainan Province · manufacturing
Hainan Poly Pharm's primary API manufacturing facility in Haikou, Hainan Province; produces paclitaxel and docetaxel API via semi-synthesis from 10-DAB sourced from Taxus chinensis cultivated in Yunnan and Sichuan Province plantations. Source: https://www.polyp.com.cn
Taxus chinensis Yew Plantations (Yunnan / Sichuan, China) →
CNYunnan Province · agricultural
Chinese yew tree (Taxus chinensis, T. yunnanensis) plantation system concentrated in Yunnan, Sichuan, and Shaanxi provinces; the primary global source of 10-deacetylbaccatin III (10-DAB) used in paclitaxel and docetaxel semi-synthesis. Chinese yew plantations are managed by provincial forestry enterprises and private agricultural companies supplying Chinese API manufacturers. Taxus chinensis cultivation in Yunnan was developed as a sustainable alternative to Pacific yew bark harvesting after the US near-extinction crisis of the early 1990s. Chinese yew plantations represent the world's largest concentration of the paclitaxel precursor feedstock. Source: https://pubs.usgs.gov/fs/2007/3095/
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Paclitaxel & Docetaxel API
70%Other Oncology APIs
20%Botanical Raw Materials
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2019
Hainan Poly Pharm's parent, Poly Group, operates simultaneously in: Chinese defense equipment exports (arms dealing), luxury arts/auction (Poly Auction is one of China's top auction houses for Western fine art and Chinese antiquities), real estate development, and oncology pharmaceutical APIs through Hainan Poly Pharm. The cancer treatment supply chain — specifically paclitaxel and docetaxel, two of the world's most critical chemotherapy drugs — is controlled in China partly by a conglomerate whose founding business was the PLA's arms export division. US oncology drug buyers purchasing generic paclitaxel may be indirectly purchasing from a supply chain that traces to a PLA-affiliated defense entity — a connection that is not disclosed in any pharma supply chain risk analysis or US Drug Administration surveillance.
Reuters ↗Concentration2023
Hainan Poly Pharm is majority-owned by Poly Group — one of China's largest state-linked conglomerates, with operations spanning defense equipment manufacturing, explosives, real estate, and cultural industries. Poly Group's involvement in paclitaxel API production through Hainan Poly Pharm represents a pattern where Chinese state-connected enterprises are embedded in the supply chains of critical oncology APIs. Poly Group is the same conglomerate that operates China's largest arms export company (China Poly Group Corporation's defense division) and that controls significant Hong Kong real estate. A pharmaceutical API manufacturer for one of the world's most important cancer drugs is a subsidiary of a Chinese state enterprise that also manufactures weapons systems — the pharmaceutical and defense industrial bases share a parent organization.
Hainan Poly Pharm / Poly Group ↗Origin2023
Hainan Poly Pharm is based in Haikou, Hainan Province — a tropical island province off southern China with subtropical forests where Taxus wallichiana (Chinese yew) grows and can be cultivated. The parent company, Poly Group Corporation (中国保利集团), was founded in 1984 as an arm of the People's Liberation Army (PLA) and originally operated as a defense equipment export company before diversifying into real estate, petrochemicals, arts/culture (Poly Culture is a leading auction house), and pharmaceuticals. Hainan Poly Pharm represents Poly Group's pharmaceutical arm, giving a Chinese state-military-linked industrial conglomerate a position in the global oncology drug supply chain.
China Poly Group ↗